Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	11.32	7.88	5.73	1.26	0.23	0.22
Revenue Growth (YoY)	67.96%	37.48%	354.68%	445.45%	7.44%	-
Gross Profit	11.32	7.88	5.73	1.26	0.23	0.22
Selling, General & Admin	22.75	22.53	22.93	18.39	9.06	5.18
Research & Development	63.45	61.54	73.12	75.66	40.36	26
Operating Expenses	86.2	84.07	96.05	94.05	49.41	31.18
Operating Income	-74.87	-76.2	-90.32	-92.79	-49.18	-30.97
Other Expense / Income	-11.85	-7	-2.22	5.8	11.55	-0.48
Pretax Income	-63.03	-69.2	-88.1	-98.59	-60.73	-30.49
Net Income	-63.03	-69.2	-88.1	-98.59	-60.73	-30.49
Shares Outstanding (Basic)	38	38	37	33	2	2
Shares Outstanding (Diluted)	38	38	37	33	2	2
Shares Change	1.02%	1.21%	12.54%	1479.05%	5.46%	20.76%
EPS (Basic)	-1.66	-1.83	-2.36	-2.97	-28.89	-15.29
EPS (Diluted)	-1.66	-1.83	-2.36	-2.97	-28.89	-15.29
Free Cash Flow	-63.08	-69.73	-78.46	-59.4	-50.57	-26.85
Free Cash Flow Per Share	-1.66	-1.84	-2.10	-1.79	-24.05	-13.47
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-661.19%	-967.45%	-1576.56%	-7364.13%	-21290.91%	-14404.19%
Profit Margin	-556.59%	-878.58%	-1537.76%	-7824.68%	-26289.18%	-14180.00%
Free Cash Flow Margin	-557.05%	-885.36%	-1369.47%	-4714.60%	-21891.77%	-12488.84%
EBITDA	-58.18	-64.39	-83.21	-94.92	-58.22	-29.16
EBITDA Margin	-513.75%	-817.56%	-1452.38%	-7533.25%	-25205.19%	-13561.86%
Depreciation & Amortization	4.85	4.81	4.89	3.67	2.5	1.33
EBIT	-63.03	-69.2	-88.1	-98.59	-60.73	-30.49
EBIT Margin	-556.59%	-878.58%	-1537.76%	-7824.68%	-26289.18%	-14180.00%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).